Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for COL30336

Result Summary for COL30336

Result Summary

Protocol ID:	COL30336
Clinical Study ID:	COL30336
Official Title:	A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) BID, ZIAGEN (Abacavir) 300mg BID, and SUSTIVA (Efavirenz) 600mg QD for 24 Weeks, Followed by Therapy with the Triple Nucleoside C ...
Phase:	Phase 4
Study Indications or Diseases:	Infection, Human immunodeficiency Virus
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	trizivir;trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Ruane P., et al. The PI-sparing compact quad regimen of Combivir/abacavir/efavirenz (COM/ABC/EFV) is potent and well-tolerated in naive subjects with high viral loads: 24-week data. In: 2001 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Salt Lake City, UT, April 22–25, 2001. Poster 47E. Parenti D., Ruane P., et. al. The Compact Quad, Combivir/Abacavir/Efavirenz (COM/ABC/EFV) Preliminary 48-Wk Result (COL30336). In: 39th Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, October 25-28, 2001. Poster 697. Ruane P., et. al. Compact Quadruple Therapy with the Lamivudine/Zidovudine Combination Tablet Plus Abacavir and Efavirenz, Followed by the Lamivudine/Zidovudine/Abacavir Triple Nucleoside Tablet Plus Efavirenz in Treatment-Naïve HIV-Infected Adults. HIV Clinical Trials 2003, 4(4), 231-243.